The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -36.92 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.20 — no flag raisedOK
- Earnings quality 81/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2024, as Scinai Immunotherapeutics Ltd. reports it. History and quarterly detail are in the app.
- License$100K
Latest filings
- 6-K · Company announcement (foreign filer)2026-08-26
- 6-K · Company announcement (foreign filer)2026-08-19
- 6-K · Company announcement (foreign filer)2026-06-17
- 6-K · Company announcement (foreign filer)2026-06-15
- 6-K · Company announcement (foreign filer)2026-06-08
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Scinai Immunotherapeutics Ltd., every answer cited to the official filings🔒
- The Intelligence Brief — added when Scinai Immunotherapeutics Ltd.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.